INTRODUCTION {#s1}
============

Graves' disease (GD) is an autoimmune thyroid disease with a prevalence of 0.5% in the general population \[[@R1]--[@R2]\]. GD is characterized by the presence of thyroid-stimulating hormone (TSH) receptor antibodies, which leads to hyperthyroidism and goiter. The exact etiology of GD remains unknown; however, it is believed that genetic polymorphisms and environmental factors are both involved in the pathogenesis of GD. Large familial clustering and twin studies have proposed that about 79% of the risk for developing GD may be related to genetic factors, whereas 21% of them were related to the environmental and endogenous factors \[[@R3]--[@R4]\]. Genome-wide association studies (GWASs) have reported loci for GD on chromosomal region 5q31-q33 in Asian populations \[[@R5]\]. This region includes the T helper 1 (Th1) and Th2 gene cluster, which encodes certain cytokines, including the inflammation-associated proteins interleukin (IL)-4, IL-12, and IL-13. In addition, another GWAS revealed that IL-6 and IL-10 are related to the pathogenesis of GD \[[@R6]--[@R8]\].

IL-4, IL-6, IL-10, and IL-12 are produced by intra-thyroidal inflammatory cells and thyroid follicular cells. IL-13 is an important immunoregulatory cytokine involved in the IgE synthesis and is associated with Th2-mediated disease. The serum levels of IgE and IL-13 may be the indicators of remission or recurrence of GD \[[@R9]--[@R10]\]. Genetic factors that affect the induction or inhibition of these cytokines are the potential candidates for GD sensitivity. Indeed, emerging studies had shown that over 70 variations in 22 IL-related genes (*IL- 1B, IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-8, IL-9, IL-10, IL-12, IL-12A, IL-13, IL-16, IL-17, IL-17F, IL-18, IL-18R, IL-21, IL-23, and IL-33*) are associated with GD. Nevertheless, the results are conflicting due to the limited sample size of each study. We, therefore, in the current report, conducted a meta-analysis of seven single nucleotide polymorphisms (SNPs) in five cytokine genes from all eligible case-control studies that included more than three studies to assess the associations among reported IL-related genes with GD.

RESULTS {#s2}
=======

Workflow for the identification of eligible datasets {#s2_1}
----------------------------------------------------

A total of 116 publications were characterized based on our keyword search. After screening the titles and abstracts, 67 studies were identified as irrelevant, and eight articles were characterized as reviews. Additionally, 17 studies were excluded because 10 of the articles focused on different genes. Another seven articles were excluded because they were not on GD research (two studies), were not case control studies (three studies), or did not assess polymorphisms (two articles). Among the remaining 24 publications, two studies were also rejected as they either failed to provide detailed genotyping information (one article) or were published in non-English journals (one study) (Figure [1](#F1){ref-type="fig"}).

![PRISMA flow diagram showing the search strategy](oncotarget-08-98993-g001){#F1}

Characteristics of the selected datasets {#s2_2}
----------------------------------------

A total of 22 case control datasets were identified based on our inclusion criteria. Of these, 22 studies, including 5338 patients with GD and 6446 healthy controls, were analyzed. The principal characteristics and genotype distributions of the identified studies are shown in Table [1](#T1){ref-type="table"}. Among the included articles, 16 studies were from Asian populations \[[@R6]--[@R7], [@R9], [@R11]--[@R23]\] and 6 studies were from European populations \[[@R24]--[@R29]\]. Genotypic distribution for all SNPs in controls was in consistent with HWE (*p* \> 0.05) except for the 3 datasets highlighted in bold (Table [1](#T1){ref-type="table"}). The quality of each study was assessed through Newcastle-Ottawa assessment scale (NOS), as shown in Table [2](#T2){ref-type="table"}. All included studies scored 7 or 8, indicating sufficient quality for their inclusion in the meta-analysis.

###### Characteristic of datasets included for meta-analysis

  ID        Author               Year        Ethnicity   Genotyping method     Study design   Gene    Case/Control   SNP loci    GD     Control   *pHWE*                     
  --------- -------------------- ----------- ----------- --------------------- -------------- ------- -------------- ----------- ------ --------- -------- ----- ----- ----- ----------
  1         Jung-Pil Jang        2016        Asian       hybridization         CC             IL-13   60/192         rs1800925   36     24        0        129   61    2     0.07
  2         Duraes               2014        European    Taqman                CC             IL-6    111/735        rs1800795   13     61        37       92    324   319   0.5
  3         Faruk Kutluturk      2013        European    PCR-SSP               CC             IL-6    100/124        rs1800795   12     36        52       6     41    77    0.86
  4         Yann-Jinn Lee        2011        Asian       Taqman                CC             IL-4    220/904        rs2243250   9      64        147      38    255   611   0.087
  5         N. Inoue             2011        Asian       PCR-RFLP              CC             IL-13   78/68          rs1800925   60     16        2        53    14    1     0.95
  6         Nan Liu              2011        Asian       GenomeLab SNPstream   CC             IL-10   725/696        rs1800872   321    326       78       299   310   87    0.63
  7         Omid Khalilzadeh     2010        Asian       PCR-SSP               CC             IL-4    107/139        rs2243250   50     52        5        10    129   0     **0.00**
  107/139   rs2070874            29          50          28                    61             78      0              **0.00**                                                
  8         W, Zhu               2010        Asian       GenomeLab SNPstream   CC             IL-4    731/716        rs2070874   453    253       25       461   231   24    0.45
  9         Mehdi Anvari         2010        Asian       PCR-SSP               CC             IL-6    107/139        rs1800795   27     63        17       4     93    42    **0.00**
  IL-12     107/140              rs3212227   34          53                    20             72      60             8           0.32                                        
  10        Kelvin K. L. Chong   2008        Asian       PCR-RFLP              CC             IL-13   177/151        rs1800925   120    51        6        106   44    1     0.11
  rs20541   68                   81          28          66                    67             18      0.87                                                                   
  11        Nanba                2008        Asian       Sequencing            CC             IL-4    50/26          rs2243250   4      22        24       2     11    13    0.88
  12        Rong-Hsing Chen      2007        Asian       GenomeLab SNPstream   CC             IL-4    104/105        rs2243250   4      32        68       2     36    67    0.25
  13        Ming-Yuh Shiau       2007        Asian       PCR-RFLP              CC             IL-10   133/134        rs1800872   62     54        17       72    52    10    0.89
  IL-4      130/101              rs2070874   93          34                    3              68      31             2           0.47                                        
  137/119   rs2243250            6           48          83                    6              35      78             0.43                                                    
  14        Yuji Hiromatsu       2006        Asian       Sequencing            CC             IL-12   329/226        rs3212227   77     162       90       39    120   67    0.24
  15        Yang                 2005        Asian       Sequencing            CC             IL-4    187/131        rs2243250   7      51        129      2     46    83    0.12
  16        Yukio Ikeda          2004        Asian       PCR-RFLP              CC             IL-12   90/123         rs3212227   22     39        29       29    64    30    0.65
  17        Yuji Hiromatsu       2004        Asian       PCR-RFLP              CC             IL-13   310/244        rs1800925   219    83        8        143   88    13    0.91
  rs20541   166                  123         21          113                   100            31      0.24                                                                   
  18        Bednarczuk, T        2004        Asian       PCR-RFLP              CC             IL-6    279/186        rs1800795   56     138       85       27    101   58    0.11
  19        Karen F, Tait        2004        European    Invader assay         CC             IL-10   630/846        rs1800872   32     234       364      35    290   521   0.50
  20        Tomasz Bednarczuk    2003        European    SSCP                  CC             IL-13   261/168        rs1800925   127    108       26       89    63    16    0.33
  rs20541   148                  94          19          94                    66             8       0.40                                                                   
  21        Heward               2001        European    PCR-RFLP              CC             IL-4    381/285        rs2243250   277    99        5        222   58    5     0.59
  22        Hunt                 2000        European    PCR-SSP               CC             IL-4    138/101        rs2243250   122    15        1        75    23    3     0.46

11: wild-type homozygote, 12: heterozygote, 22: variant homozygote.

CC: case/control.

HWE: Hardy-Weinberg equilibrium.

PCR-SSCP: PCR-single-strand conformation polymorphism.

PCR-SSP: PCR-sequence specific primer.

###### Quality assessments of case-control studies according to the Newcastle Ottawa Scale

  Study ID   Author               Year   Selection   Comparability   Exposure   Total score                                      
  ---------- -------------------- ------ ----------- --------------- ---------- ------------- ------ ------ ------ ------ ------ ---
  1          Jung-Pil Jang        2016   ^\*^        ^\*^            /          /             ^\*^   ^\*^   ^\*^   ^\*^   ^\*^   7
  2          Duraes               2014   ^\*^        ^\*^            /          ^\*^          ^\*^   ^\*^   ^\*^   ^\*^   ^\*^   8
  3          Faruk Kutluturk      2013   ^\*^        ^\*^            /          ^\*^          ^\*^   ^\*^   ^\*^   ^\*^   ^\*^   8
  4          Yann-Jinn Lee        2011   ^\*^        ^\*^            /          ^\*^          ^\*^   ^\*^   ^\*^   ^\*^   ^\*^   8
  5          N. Inoue             2011   ^\*^        ^\*^            /          /             ^\*^   ^\*^   ^\*^   ^\*^   ^\*^   7
  6          Nan Liu              2011   ^\*^        ^\*^            /          ^\*^          ^\*^   ^\*^   ^\*^   ^\*^   ^\*^   8
  7          Omid Khalilzadeh     2010   ^\*^        ^\*^            /          ^\*^          ^\*^   /      ^\*^   ^\*^   ^\*^   7
  8          W, Zhu               2010   ^\*^        ^\*^            /          ^\*^          ^\*^   ^\*^   ^\*^   ^\*^   ^\*^   8
  9          Mehdi Anvari         2010   ^\*^        ^\*^            /          ^\*^          ^\*^   /      ^\*^   ^\*^   ^\*^   7
  10         Kelvin K. L. Chong   2008   ^\*^        ^\*^            /          ^\*^          ^\*^   ^\*^   ^\*^   ^\*^   ^\*^   8
  11         Nanba                2008   ^\*^        ^\*^            /          /             ^\*^   ^\*^   ^\*^   ^\*^   ^\*^   7
  12         Rong-Hsing Chen      2007   ^\*^        ^\*^            /          ^\*^          ^\*^   ^\*^   ^\*^   ^\*^   ^\*^   8
  13         Ming-Yuh Shiau       2007   ^\*^        ^\*^            /          /             ^\*^   ^\*^   ^\*^   ^\*^   ^\*^   7
  14         Yuji Hiromatsu       2006   ^\*^        ^\*^            /          ^\*^          ^\*^   ^\*^   ^\*^   ^\*^   ^\*^   8
  15         Yang                 2005   ^\*^        ^\*^            /          ^\*^          ^\*^   /      ^\*^   ^\*^   ^\*^   
  16         Yukio Ikeda          2004   ^\*^        ^\*^            /          ^\*^          ^\*^   ^\*^   ^\*^   ^\*^   ^\*^   8
  17         Yuji Hiromatsu       2004   ^\*^        ^\*^            /          ^\*^          ^\*^   ^\*^   ^\*^   ^\*^   ^\*^   8
  18         Bednarczuk, T        2004   ^\*^        ^\*^            /          /             ^\*^   ^\*^   ^\*^   ^\*^   ^\*^   7
  19         Karen F, Tait        2004   ^\*^        ^\*^            /          ^\*^          ^\*^   /      ^\*^   ^\*^   ^\*^   7
  20         Tomasz Bednarczuk    2003   ^\*^        ^\*^            /          /             ^\*^   ^\*^   ^\*^   ^\*^   ^\*^   7
  21         Heward               2001   ^\*^        ^\*^            /          ^\*^          ^\*^   /      ^\*^   ^\*^   ^\*^   7
  22         Hunt                 2000   ^\*^        ^\*^            /          ^\*^          ^\*^   /      ^\*^   ^\*^   ^\*^   7

Publication quality check list:

a: Is the case definition adequate?;

b: Representativeness of the cases;

c: Selection of Controls;

d: Definition of Controls;

e: study controls for ethnicity;

f: study controls for any additional factor;

g: Ascertainment of exposure;

h: Same method of ascertainment for cases and controls;

i: Non-Response rate.

Association between IL-related gene polymorphism and Graves' disease {#s2_3}
--------------------------------------------------------------------

We performed a meta-analysis of seven SNPs in five *IL* -related genes, including *IL-4* (rs2243250 and rs2070874), *IL-6* (rs1800795), *IL-10* (rs1800872), *IL-12* (rs3212227), and *IL-13* (rs1800925 and rs20541). The number of the included datasets on each SNP ranged from 3 to 8. Unexpectedly, only one SNP (rs1800795) in *IL-6* was found to have a significant association with GD in the homozygous model (CC vs. GG: OR = 2.714, 95% CI = 1.047 - 7.039, *p* = 0.04), heterozygous model (CG vs. GG: OR = 1.295, 95% CI = 1.013 - 1.655, *p* = 0.039), dominant model (CC+CG vs. GG: OR = 1.418, 95% CI = 1.122 - 1.793, *p* = 0.003) and additive model(C vs. G: OR = 1.432, 95% CI = 1.087 - 1.886, *p* = 0.011) (Table [2](#T2){ref-type="table"}; Figure [2](#F2){ref-type="fig"}). Our meta-analysis of rs1800795 was hampered by high heterogeneity. A random effect model was thus used. To explain the heterogeneity, we performed the subgroup analysis by ethnicity. The ethnicity stratification revealed that the association between rs1800795 and GD tended to be much stronger for Asian populations than for European populations in the homozygous, dominant, recessive, and additive models ([Supplementary Figure 1](#SD1){ref-type="supplementary-material"}).

![Forest plot for the association between *IL-6* rs1800795 polymorphism and Graves' disease\
(**A**) homozygous model (CC vs. GG), (**B**) heterozygous model (CG vs. GG), (**C**) dominant model (CC+CG vs. GG), (**D**) additive model (C vs. G).](oncotarget-08-98993-g002){#F2}

The remaining 6 SNPs in the 4 genes did not show significant association with GD in any genetic model (Table [3](#T3){ref-type="table"}). Among the insignificant polymorphisms, rs2243250 in *IL-4* (I^2^ \< 85.2%), rs2070874 in *IL-4* (I^2^ \< 88.8%), rs1800872 in *IL-10* (I^2^ \< 53.3%), rs3212227 in *IL-12* (I^2^ \< 87.0%), rs1800925 in *IL-13* (I^2^ \< 63.9%), and rs20541 in *IL-13* (I^2^ \< 75.9%) were hampered by high heterogeneity. Considering the limited number of studies, we only performed subgroup analysis of variations with more than 3 articles (rs2243250 in *IL-4* and rs1800925 in *IL-13*). Ethnicity stratification showed that these two SNPs did not show significant associations with GD in Asian and European populations ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}).

###### Results for meta-analysis of polymorphism within Interleukin related genes with Graves' disease risk

  Gene    Polymorphism   No. of datasets   Ethnicity         Genetic model          OR(95% CI)             *p* value   Test of heterogeneity   *p* for publication bias^a^   
  ------- -------------- ----------------- ----------------- ---------------------- ---------------------- ----------- ----------------------- ----------------------------- --------
  IL-4    rs2243250      8                 Asian, European   CC vs. TT              1.225 (0.777, 1.931)   0.382       0%                      0.86                          0.308
                                           CT vs. TT         0.959 (0.776, 1.184)   0.695                  21.8%       0.256                   0.629                         
                                           CC+CT vs. TT      0.988 (0.806, 1.211)   0.905                  0%          0.431                   0.872                         
                                           CC vs. CT+TT      1.800 (0.814, 3.981)   0.147                  85.2%       0.000                   0.378                         
                                           C vs. T           1.188 (0.906, 1.557)   0.213                  69.8%       0.002                   0.392                         
  IL-4    rs2070874      3                 Asian, European   CC vs. TT              0.261 (0.02,3.366)     0.303       86.2%                   0.001                         0.451
                                           CT vs. TT         0.273 (0.022,3.4710    0.317                  85.7%       0.001                   0.386                         
                                           CC+CT vs. TT      0.269 (0.02,3.551)     0.319                  86.6%       0.001                   0.430                         
                                           CC vs. CT+TT      0.871 (0.526,1.27)     0.369                  68.0%       0.044                   0.810                         
                                           C vs. T           0.747 (0.416,1.342)    0.330                  88.8%       0.000                   0.763                         
  IL-6    rs1800795      4                 Asian, European   CC vs. GG              2.714 (1.047, 7.039)   0.04        81.6%                   0.01                          0.117
                                           CG vs. GG         1.295 (1.013, 1.655)   0.039                  24.4%       0.265                   0.541                         
                                           CC+CG vs. GG      1.418 (1.122, 1.793)   0.003                  37.2%       0.189                   0.178                         
                                           CC vs. CG+GG      2.305 (0.947, 5.613)   0.066                  82.1%       0.001                   0.221                         
                                           C vs. G           1.432 (1.087, 1.886)   0.011                  64.3%       0.038                   0.228                         
  IL-10   rs1800872      3                 Asian, European   AA vs. CC              1.123 (0.86,1.467)     0.394       48.1%                   0.146                         0.388
                                           AC vs. CC         1.127 (0.942,1.35)     0.191                  40%         0.366                   0.299                         
                                           AA+AC vs. CC      1.135 (0.955,1.348)    0.15                   36.3%       0.208                   0.280                         
                                           AA vs. AC+CC      1.028 (0.86,1.23)      0.761                  10.8%       0.326                   0.816                         
                                           A vs. C           1.065 (0.953,1.19)     0.265                  53.3%       0.117                   0.276                         
  IL-12   rs3212227      3                 Asian             CC vs. AA              0.634 (0.206,1.949)    0.427       86.7%                   0.001                         0.2114
                                           CA vs. AA         0.677 (0.384,1.193)    0.177                  59.8%       0.083                   0.039                         
                                           CC+CA vs. AA      0.636 (0.3,1.348)      0.237                  79.3%       0.008                   0.095                         
                                           CC vs. CA+A       0.883 (0.417,1.869)    0.744                  83.7%       0.002                   0.729                         
                                           C vs. A           0.804 (0.473,1.367)    0.421                  87.0%       0.000                   0.388                         
  IL-13   rs1800925      5                 Asian, European   TT vs. CC              1.056 (0.652,1.712)    0.824       38%                     0.164                         0.595
                                           TC vs. CC         1.018 (0.616,1.68)     0.946                  0%          0.489                   0.471                         
                                           TT+TC vs. CC      1.055 (0.656,1694)     0.826                  23.8%       0.263                   0.556                         
                                           TT vs. TC+CC      1.009 (0.712,1.429)    0.961                  61.1%       0.036                   0.363                         
                                           T vs. C           1.005 (0.739,1.367)    0.974                  63.9%       0.026                   0.438                         
  IL-13   rs20541        3                 Asian, European   AA vs. GG              1.014 (0.44,2.337)     0.973       75.9%                   0.016                         0.467
                                           AG vs. GG         0.991 (0.504,1.949)    0.978                  62.7%       0.068                   0.406                         
                                           AA+AG vs. GG      1.006 (0.473,2.14)     0.987                  72.9%       0.025                   0.499                         
                                           AA vs. AG+GG      1.083 (0.869,1.35)     0.476                  39.7%       0.19                    0.005                         
                                           A vs. G           1.036 (0.756,1.418)    0.828                  70%         0.036                   0.146                         

^a^:Egger's test was performed to assess publication bias.

Publication bias {#s2_4}
----------------

Begg\'s funnel plot and Egger\'s test were performed to assess the publication bias. The shape of the funnel plots appeared to be symmetrical (SNP rs1800795 in *IL-6*) and the Egger\'s test did not show any evidence of publication bias (Figure [3](#F3){ref-type="fig"}). The sensitivity analyses also indicated that results of our study were stable and reliable (data not shown).

![Funnel plot analysis to detect publication bias (SNP rs1800795 in *IL-6*)\
Each point represents a separate study for the indicated association. (**A**) homozygous model (CC vs. GG), (**B**) heterozygous model (CG vs. GG), (**C**) dominant model (CC+CG vs. GG), (**D**) additive model (C vs. G).](oncotarget-08-98993-g003){#F3}

DISCUSSION {#s3}
==========

In the present study, we examined the association between variations in IL-related genes and GD. The results of our overall meta-analysis supported that only G-\>C mutation at rs1800795 in IL-6 was a risk factor for GD. The other 6 variations in the 4 genes (IL-4 rs2243250, IL-4 rs2070874, IL-10 rs1800872, IL-12 rs3212227, IL-13 rs1800925 and IL-13 rs20541) did not show a significant association with GD in any genetic model. Considering the fact that the ethnic background may affect the results of genetic association studies, we performed a subgroup analysis by ethnicity and found that the association was more apparent among Asian populations, indicating that IL-6 polymorphism may exert varying effects in different populations. This is perhaps because different populations are exposed to diverse environments during their evolution and different life styles. These results were consistent with the findings of Mehdi Anvari *et al* in an Iranian population \[[@R14]\]. IL-6 plays an important role in the growth and differentiation of lymphocytes, which might contribute to the promotion of thyroid receptor antibody synthesis during the course of GD. IL-6 rs1800795, which is located in the 5′ promoter region at position -174(G-174C), appears to influence IL-6 production. Moreover, there are evidences indicating that the C allele results in lower transcriptional activity than the G allele \[[@R30]--[@R31]\]. In line with this notion, subjects carrying the putative risk C/C genotype show lower plasma IL-6 levels than subjects carrying the G/G genotype. These findings suggest that the IL6 rs1800795 polymorphism is functional and may be related to the pathogenesis of GD.

Except for IL-6, six variations in these genes (*IL-4* rs2243250, *IL-4* rs2070874, *IL-10* rs1800872, *IL-12* rs3212227, *IL-13* rs1800925, and *IL-13* rs20541) did not show significant associations with GD in our meta-analysis. IL-10 is a major anti-inflammatory cytokine that is secreted by activated T cells, B cells, monocytes, and thymocytes \[[@R32]\]. *IL-10* rs1800872 showed no association with GD in all of the tested population and had no heterogeneity. Thus, it is not likely to be a genetic marker for GD. Another five insignificant SNPs (*IL-4* rs2243250, *IL-4* rs2070874, *IL-12* rs3212227, *IL-13* rs1800925, and *IL-13* rs20541) also did not show an association with GD in all of the tested population with mild to high heterogeneities. IL-4 is a member of Th2 cytokines with anti-inflammatory properties, which reduces the production of proinflammatory cytokines and destructive enzymes by monocytes. Interestingly, we found that there were inconsistent conclusions even within the same ethnic group. For example Nanba and colleagues showed that rs2243250 in *IL-4* was significantly associated with GD in the Japanese population \[[@R16]\], whereas Lee and colleagues failed to detect an association between *IL-4* polymorphisms (rs2243250) and GD risk in a Chinese dataset \[[@R13]\]. This discrepancy is likely due to the differences in their lifestyle and diet, social and emotional stress, as well as their medical care and economic conditions. Of course, other factors such as study design and limited sample size, may also contribute to such discrepancies. Given that the associations between these genes and GD are still controversial, further replication studies of *IL-4* gene among different population are warranted. IL-13 is an important immunoregulatory protein produced primarily by activated Th2 cells and is involved in B cell maturation. High serum IL-13 levels have been observed in patients with GD, which decrease significantly after treatment, suggesting that IL-13 gene polymorphisms are contributing to the development and severity of GD. However, we did not detect association of IL-13 with GD in our meta-analysis. This may be due to the limited number of included studies. IL-12 is an important cytokine that regulates innate resistance and adaptive immunity \[[@R33]--[@R34]\]. It has been demonstrated that the imbalance between Th1 and Th2 cytokine production is highly correlated with the induction and development of several autoimmune diseases including GD. Although rs3212227 in *IL-12* are not significant in our meta-analysis, another SNP in IL-12 (rs568408) had show significant association with GD \[[@R35]\]. For this reason, the contributing role of the genetic variants of IL-12 needs further conformation in specific population.

Our meta-analysis has some key advantages. First, although other authors published such meta-analysis, they only studied the association between one of the interleukin genes and GD. However, our meta-analysis evaluated the "functional synergies" of Th1 (IL-12) and Th2 (IL-4, IL-6, IL-10 and IL-13) cytokines in autoimmune inflammation in the GD. Second, to guarantee the quality of this study, we included the most updated literature and used explicit criteria for study inclusion and a strict procedure for data extraction. Third, a substantial number of subjects were pooled from individual studies, which significantly increased the statistical power. However, there are several limitations in our study. First, the controls were hospital-based study in our included literatures. Compared with hospital-based study, a population-based case-control study can reduce more selection bias and have higher confidence. Second, our search was restricted to English-language studies. Some potential studies which were published in other languages or unpublished have been systematically excluded. This may explain some publication bias in our meta-analysis, which may have affected the results of this meta-analysis in as far as those studies that had produced negative results might not have been published. Third, the small number of published studies may lead to erroneous conclusions, especially among different ethnic group. What\'s more, since we were not able to obtain the original data, our further evaluation of gene-to-environment interactions was limited.

In summary, the results of our meta-analysis identified that only rs1800795 within the *IL-6* gene is associated with increased risk for developing GD. Owing to the limited number of included studies, future studies with a large dataset focusing on address their functional relevance would be necessary for fully establishing their effect on GD susceptibility.

MATERIALS AND METHODS {#s4}
=====================

Eligible studies {#s4_1}
----------------

PubMed, EMBASE and ISI Web of Science were searched (the last search was conducted on March 1, 2017) using the following search terms: "ILs" or "interleukins" and "Graves' disease" and "polymorphism". Reference, which were listed in each identified article, were also searched manually to identify additional eligible studies.

Validity assessment {#s4_2}
-------------------

To be eligible, the following inclusion criteria were established: (1) a human case-control study of a polymorphism associated with Graves' disease; (2) studies that included sufficient genotype data for extraction. Main exclusion criteria of studies were as follows: (1) case reports, letters, reviews, and editorial articles; (2) literature not containing information regarding diabetes research; (3) study involving only a case population; and (4) study not written in English. In the case of multiple studies by the same researchers involving the same or overlapping data sets, we selected the most recent study with the largest number of participants.

Data extraction and quality assessment {#s4_3}
--------------------------------------

Two curators (Yaqin Tu and Guorun Fan) independently extracted information from included studies. Disagreement was resolved by discussion between the two authors. The following data were extracted: first author\'s name, year of publication, the ethnicities of the individuals involved, the genotyping method, number of cases and controls for each genotype, and the Hardy-Weinberg equilibrium (HWE) among the controls. Ethnicity was categorized as East Asian and European. A double-check procedure was performed to ensure accuracy of data entry. To evaluate the quality of included studies, we adopted the Newcastle-Ottawa Scale (NOS) with a nine-star system; this scale assesses the quality of cohort and case-control studies. NOS focuses on three separate sections of stars represents the assessment score. The maximal score of NOS is 9 stars: 4 stars for the selection process, 2 stars for comparability, and 3 stars for exposure/outcome. A score of seven and above was represents the high-quality of study.

Statistical analysis {#s4_4}
--------------------

The strength of associations between IL-related genes and Graves' disease risk was measured by ORs with 95% CIs. We explored the association between IL-related genes and Graves' disease in homozygote (XX vs. xx), heterozygote (Xx vs. xx), dominant (Xx + XX vs. xx), recessive (XX vs. Xx + xx), and additive (X vs. x) models respectively. Hardy--Weinberg equilibrium (HWE) was evaluated by the goodness-of-fit *χ2* test for genotypes in the control group. Chi-squared-based *Q*-statistic test was employed to assess the between-study heterogeneity, and in any case *p* \< 0.10 was considered with significant heterogeneity between datasets. Once the effects were assumed to be homogenous, fixed-effects model was then applied (the Mantel-Haenszel method); otherwise, the random-effects model (DerSimonian and Laird method) was employed appropriately. Sensitivity analysis was performed to assess the influence of each individual study by omitting 1 study at a time and calculating a pooled estimate for the remainder of the studies. The inverted funnel plots and Egger\'s regression test were used to investigate publication bias. Potential publication bias was assessed with funnel plots of the effect sizes versus the standard errors; Begg\'s test was used to identify significant asymmetry. If there is evidence of publication bias, funnel plot is noticeably asymmetric. Concerning the significance level of the Begg\'s and Egger\'s tests was set at 0.05. All statistical tests carried out in the present report were two tailed. All analyses were conducted using the Review Manager 5.0.23 (Cochrane Library Software, Oxford, UK) and STATA 11.0 software (STATA Corporation, College Station, TX, USA).

SUPPLEMENTARY MATERIALS FIGURE AND TABLE {#s5}
========================================
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GD

:   Graves' disease

IL

:   Interleukin

Th1

:   T helper 1

TSH

:   thyroid-stimulating hormone

GWAS

:   genome-wide association studies

NOS

:   Newcastle-Ottawa Scale

CI

:   confidence interval

OR

:   odds ratio

SNPs

:   single nucleotide polymorphisms

HWE

:   Hardy-Weinberg equilibrium
